| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | 60.4% | n/a |
| ROCE | 2.4% |
| Latest | F'cast | |
|---|---|---|
| P/E | 44.9 | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | 17.8 | n/a |
| Pr/Book | 0.7 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 322.2% | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-21 | 0.66 | (7.80) | (3.67)¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-22 | 2.17 | (5.29) | (2.24)¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-23 | 4.17 | (4.76) | (2.26)¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-24 | 8.19 | (8.74) | (2.60)¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-25 | 34.57 | 13.75 | 4.21¢ | 51.3 | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Transaction in Own Shares | 02-Apr-2026 | 07:00 | RNS |
| Total Voting Rights | 01-Apr-2026 | 07:01 | RNS |
| Apellis and Centessa to be acquired | 01-Apr-2026 | 07:00 | RNS |
| RTW Biotech portfolio co Aktis Oncology raises $... | 12-Jan-2026 | ShareCast |
| Total Voting Rights | 02-Jan-2026 | ShareCast |
No deals were found in the last 28 days.
| Currency | US Dollars |
| Share Price | $ 2.01 |
| Change Today | $ -0.02 |
| % Change | -0.99 % |
| 52 Week High | $2.3 |
| 52 Week Low | $1.1 |
| Volume | 672,545 |
| Shares Issued | 325.22m |
| Market Cap | $653.70m |
| Beta | 0.00 |
| RiskGrade | 206 |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:47 | 1,552 @ $2.01 |
| 16:35 | 37,660 @ $2.01 |
| 16:35 | 2,749 @ $2.01 |
| 16:35 | 743 @ $2.01 |
| 16:35 | 18,305 @ $2.01 |
| Chair | William (Bill) Simpson |
You are here: research